STOCK TITAN

LLY Form 4: Director Increases Direct Holdings to 9,401.724 Shares

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Jamere Jackson, identified as a Director of Eli Lilly & Co. (LLY), reported an acquisition of 200 shares of the company’s common stock on 08/08/2025 at a reported price of $639.563 per share. The Form 4 shows his ownership following the transaction as 9,401.724 shares, held directly.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small insider purchase; immaterial to valuation but indicates personal investment by a board member.

The Form 4 records a straightforward purchase of 200 shares at $639.563 per share, with the transaction coded as P. Relative to Eli Lilly’s market capitalization, this purchase is too small to move valuation or signal a material change in insider positions. It does, however, reflect a director adding to a direct holding of 9,401.724 shares, a routine disclosure that investors monitor for alignment.

TL;DR: A modest director buy that marginally increases insider alignment but is not material on its own.

The filing lists Jamere Jackson as a Director and reports a purchase that increases his direct beneficial ownership to 9,401.724 shares. While insider purchases can signal confidence, the size here is small versus company scale. The form is properly signed by an authorized designee, indicating standard compliance with Section 16 reporting.

Insider JACKSON JAMERE
Role Director
Bought 200 shs ($128K)
Type Security Shares Price Value
Purchase Common Stock 200 $639.563 $128K
Holdings After Transaction: Common Stock — 9,401.724 shares (Direct)
Footnotes (1)
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JACKSON JAMERE

(Last) (First) (Middle)
LILLY CORPORATE CENTER

(Street)
INDIANAPOLIS IN 46285

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/08/2025 P 200 A $639.563 9,401.724 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Jonathan Groff for Jamere Jackson, pursuant to authorization on file 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jamere Jackson report on the Form 4 for LLY?

He reported acquiring 200 shares of Eli Lilly common stock at $639.563 per share on 08/08/2025, resulting in 9,401.724 shares beneficially owned (direct).

What is Jamere Jackson's role at Eli Lilly?

The Form 4 lists Jamere Jackson as a Director of Eli Lilly & Co.

How many shares does Jamere Jackson own after the reported transaction?

The report shows 9,401.724 shares beneficially owned following the transaction, held directly.

What transaction code is shown on the Form 4?

The transaction is reported with code P in the Form 4 table.

Who signed the Form 4 on behalf of the reporting person?

The signature block shows /s/ Jonathan Groff signing for Jamere Jackson 'pursuant to authorization on file'.